ArticleArchivum immunologiae et therapiae experimentalis2014
Flow cytometric analysis of CD133- and EpCAM-positive cells in the peripheral blood of patients with lung cancer.
Article in Archivum immunologiae et therapiae experimentalis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Ultrasensitive electrochemical immunosensor system for the determination of CD133 biomarker.Analytical and bioanalytical chemistry · 2025Article
- Plasma Extracellular Vesicle Long RNA in Diagnosis and Prediction in Small Cell Lung Cancer.Cancers · 2022Article
- Expression level of epithelial cell adhesion molecule (EpCAM) of circulating tumor cells (CTCs) of patients with NSCLC as an early indicator to monitor the effects of postoperative adjuvant chemotherapy.Translational cancer research · 2021Article
- Review
- Silencing of MicroRNA-503 in Rat Mesenchymal Stem Cells Exerts Potent Antitumorigenic Effects in Lung Cancer Cells.OncoTargets and therapy · 2021Article
- Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.Frontiers in immunology · 2021Article
- The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance.Cancers · 2020Review
- Article
- Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.BMC cancer · 2019Observational
- Article
- A Polyamidoamine Dendrimer-Based Electrochemical Immunosensor for Label-Free Determination of Epithelial Cell Adhesion Molecule- Expressing Cancer Cells.Sensors (Basel, Switzerland) · 2019Article
- Article
- PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.Stem cell reviews and reports · 2019Article
- New Frontiers for Molecular Pathology.Frontiers in medicine · 2019Review
- Abstracts from the European Respiratory Society Annual Conference 2018 on Thoracic Oncology.Journal of thoracic disease · 2018Article
- Novel triple‑positive markers identified in human non‑small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics.Oncology reports · 2018Article
- NRP1-positive lung cancer cells possess tumor-initiating properties.Oncology reports · 2018Article
- Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.Oncotarget · 2017Review
- Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133BMC cancer · 2017Article
- Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients.Scientific reports · 2017Article
Corrections and comments
- Comment on
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung tumors are characterized by their high metastatic potential, which is the main cause of therapeutic failure. However, the exact cellular origin of metastasis remains unknown. Since the introduction of the cancer stem cell theory, lung cancer stem cells (LCSCs) have been thought to represent metastasis-founding cells. The current study aimed to evaluate whether LCSCs could be found in the circulation. Expression of the stem cell markers CD133 and EpCAM was confirmed in tumor and normal lung tissue by flow cytometry. Then, this technique was further used to investigate the expression of CD133 and EpCAM in the peripheral blood of 41 patients with primary lung cancer. Putative LCSCs (CD133?EpCAM?) were present in 6/7 tumor samples, and CD133?EpCAM? cells were identified in the blood samples of 15 patients at a median level of 40/ml of blood. EpCAM? cells were detected in 60 % of the patients, and the number of these cells was higher in patients with adenocarcinoma than patients with squamous cell carcinoma and was also higher in patients with less advanced disease. Moreover, the frequency of this subpopulation significantly correlated with the circulating level of SSEA-4? cells. Additionally, CD133?EpCAM- cells were found in 87 % of the patients, and the numbers of these cells were significantly higher in patients with distant metastases and correlated with disease stage. This study confirmed the presence of an LCSC subpopulation with a CD133?EpCAM? phenotype in the tumors and blood of patients with lung cancer, and these results suggest an important role for CD133 and EpCAM in lung cancer progression and their potential application as novel biomarkers of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.